PENTA8/ PERA (Paediatric Evaluation of Resistance Assays)

Medical Research Council (MRC) (UK)0 个研究点目标入组 180 人开始时间: 2001年1月3日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Confirmed HIV-infected
•2. Age 3 months to 18 years
•3. Currently receiving and stable on the same antiretroviral therapy for at least 1 month; OR, if not on therapy, stopped within the last 2 weeks
•4. Parents/guardians, and children where appropriate, are willing and able to give informed consent
•5. Previous exposure to two or three classes of antiretroviral drugs, or, if exposed to nucleoside analogue reverse transcriptase inhibitors (NRTI) only, either exposed to three NRTI or two NRTI for more than 2 years
•6. The paediatrician is likely to change treatment
•7. Most recent HIV RNA result was >2000 copies/ml
•8. Paediatrician and parents are willing to wait 3 weeks for the resistance assay result before switching therapy
•9. Local resistance testing will not be done during the trial

•1. A previous resistance test, assessing both reverse transcriptase and protease inhibitor drug resistance has been performed while the child is on the current regimen. Children who have had a test on a previous regimen may be enrolled to a maximum recruitment of 30 children.
•2. Unlikely to comply with the routine schedule of visits

发起方

Medical Research Council (MRC) (UK)